RSV Vaccine
Summary: 2025–2026 RSV Vaccine Program (Ontario Public Health) 🔹 General Program Overview 🔹 1. Infant and High-Risk Children Eligibility Product 1: Beyfortus® Product 2: Abrysvo™ 🔹 2. High-Risk Older Adult RSV Vaccine Program (2025–2026) Eligibility Other details 🔹 3. Operational / Administration Notes Population Group Product Eligibility Criteria Timing Key Notes Infants < 8 months Beyfortus® (nirsevimab) Born on/after Apr 1 2025 AND < 8 months at season start Early Oct onward Single dose; preferred option for infant protection Children…